1.Andersen HS, Olsen OH, Iversen LF, Sørensen AL, Mortensen SB, Christensen MS, Branner S, Hansen TK, Lau JF, Jeppesen L, Moran EJ, Su J, Bakir F, Judge L, Shahbaz M, Collins T, Vo T, Newman MJ, Ripka WC, Møller NP.. (2002) Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B., 45 (20):[PMID:12238924][10.1021/jm0209026]
2.Zhou M, Ji M.. (2005) Molecular docking and 3D-QSAR on 2-(oxalylamino) benzoic acid and its analogues as protein tyrosine phosphatase 1B inhibitors., 15 (24):[PMID:16230012][10.1016/j.bmcl.2005.08.078]
3.Vidović D, Schürer SC.. (2009) Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design., 52 (21):[PMID:19810703][10.1021/jm9008899]
4.Cheng Y, Zhou M, Tung CH, Ji M, Zhang F.. (2010) Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues., 20 (11):[PMID:20452766][10.1016/j.bmcl.2010.04.033]
5.Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A.. (2020) Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus., 207 [PMID:32871344][10.1016/j.ejmech.2020.112742]
